AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home Food Science Article
PDF (8.2 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese | Open Access

Evaluation of Antidepressant Compounds in Ganoderma lucidum Using Network Pharmacology

Rongwei KOU1 Xinyi YANG1Yangqing HE1 ( )Bing XIA2Junchao LIU1Beita ZHAO2Xuebo LIU2
School of Science, Xi’an University of Technology, Xi’an 710054, China
College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China
Show Author Information

Abstract

Systematic prediction of potential antidepressant compounds in Ganoderma lucidum and their target proteins as well as related signaling pathways was carried out employing network pharmacology and molecular docking. A mouse model of depression was then used to validate the antidepression efficacy and mechanism of action of the bioactive compounds. Our network-based analysis identified a “G. lucidum-bioactive compounds-intersection target-depression” interaction network, revealing 19 active constituents, including lucidone A, methyl lucidente Q, and cerevisterol, as well as 122 antidepression-related targets, such as serine/threonine-protein kinase 1 (AKT1), estrogen receptor 1 (ESR1), and interleukin-6 (IL-6). The core active compounds were predicted to exert their antidepression effects through various pathways, including the neuroactive ligand-receptor interaction pathway, neurodegeneration-related pathways, the phosphatidylinositol 3-kinase/protein kinase B (PI3K-AKT) signaling pathway, the cyclic adenosine monophosphate (cAMP) signaling pathway, and the mitogen-activated protein kinase (MAPK) signaling pathway. Molecular docking analysis demonstrated that the binding affinities of the core active compounds of G. lucidum, lucidone A, methyl lucidente Q, and cerevisterol, to key target proteins were all ≤ -7.0 kcal/mol. The results of network pharmacology corroborated that lucidone A had potential antidepression activity. Animal experiments further confirmed that lucidone A significantly alleviated depression-like behaviors in mice, ameliorated neuronal morphological damage in brain tissue, and reduced neurotransmitter concentrations. Moreover, lucidone A markedly suppressed the expression of pro-inflammatory mediators, including inducible iinducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-α, IL-6, IL-1β, and IL-17, thereby exerting its antidepressant effect. These findings provide a scientific foundation for the application of G. lucidum in functional food development.

CLC number: TS201.4 Document code: A Article ID: 1002-6630(2025)15-0194-11

References

【1】
【1】
 
 
Food Science
Pages 194-204

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
KOU R, YANG X, HE Y, et al. Evaluation of Antidepressant Compounds in Ganoderma lucidum Using Network Pharmacology. Food Science, 2025, 46(15): 194-204. https://doi.org/10.7506/spkx1002-6630-20250225-129

692

Views

8

Downloads

0

Crossref

1

Scopus

0

CSCD

Received: 25 February 2025
Published: 15 August 2025
© Beijing Academy of Food Sciences 2025.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).